Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Shares Outstanding (2021 - 2025)

Verrica Pharmaceuticals has reported Shares Outstanding over the past 5 years, most recently at $17.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $17.2 million for Q4 2025, up 87.07% from a year ago — trailing twelve months through Dec 2025 was $17.2 million (up 87.07% YoY), and the annual figure for FY2025 was $17.2 million, up 87.07%.
  • Shares Outstanding for Q4 2025 was $17.2 million at Verrica Pharmaceuticals, up from $9.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for VRCA hit a ceiling of $42.2 million in Q3 2023 and a floor of $105144.0 in Q3 2021.
  • Median Shares Outstanding over the past 5 years was $13.3 million (2025), compared with a mean of $18.9 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 99.62% in 2022 and later soared 39804.51% in 2023.
  • Verrica Pharmaceuticals' Shares Outstanding stood at $105144.0 in 2021, then surged by 39083.59% to $41.2 million in 2022, then plummeted by 89.68% to $4.3 million in 2023, then skyrocketed by 116.11% to $9.2 million in 2024, then soared by 87.07% to $17.2 million in 2025.
  • The last three reported values for Shares Outstanding were $17.2 million (Q4 2025), $9.5 million (Q3 2025), and $9.3 million (Q2 2025) per Business Quant data.